Francois M Cady

Publications (6)24.86 Total impact

• Article: Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course.

  Francois M Cady, Brian Patrick O'Neill, Mark E Law, Paul A Decker, David M Kurtz, Caterina Giannini, Alyx B Porter, Paul J Kurtin, Patrick B Johnston, Ahmet Dogan, Ellen D Remstein
  [show abstract] [hide abstract]
  ABSTRACT: Primary CNS lymphoma (PCNSL) is an aggressive lymphoma but clinically validated biologic markers that can predict natural history to tailor treatment according to risk are lacking. Several genetic changes including BCL6 rearrangements and deletion of 6q22, containing the putative tumor suppressor gene PTPRK, are potential risk predictors. Herein we determined the prevalence and survival impact of del(6)(q22) and BCL6, immunoglobulin heavy chain (IGH), and MYC gene rearrangements in a large PCNSL cohort treated in a single center. Interphase fluorescence in situ hybridization was performed using two-color probes for BCL6, MYC, IGH-BCL6, and del(6)(q22) on thin sections of 75 paraffin-embedded samples from 75 HIV-negative, immunocompetent patients newly diagnosed with PCNSL. Survival data were analyzed using Kaplan-Meier survival curves, log-rank tests, and proportional hazards regression adjusting for age, deep structure involvement, and high-dose methotrexate (HDMTX) treatment. The prevalence of del(6)(q22) and BCL6, IGH, and MYC translocations was 45%,17%, 13%, and 3%, respectively. The presence of del(6)(q22) and/or a BCL6 translocation was associated with inferior overall survival (OS; P = .0097). The presence of either del(6)(q22) alone or a BCL6 translocation alone was also associated with inferior OS (P = .0087). Univariable results held after adjusting for age, deep structure involvement, and HDMTX. Del (6)(q22) and BCL6 rearrangements are common in PCNSL and predict for decreased OS independent of deep structure involvement and HDMTX. Unlike systemic diffuse large B-cell lymphoma, del(6)(q22) is common and IGH translocations are infrequent and usually involve BCL6 rather than BCL2, suggesting a distinct pathogenesis.
  Journal of Clinical Oncology 10/2008; 26(29):4814-9. · 18.37 Impact Factor
• Source

  Available from: cytometry.cn

  Article: Flow cytometric assessment of T-cell chronic lymphoproliferative disorders.

  Francois M Cady, William G Morice
  [show abstract] [hide abstract]
  ABSTRACT: Flow cytometry is frequently used in the evaluation of potential T-cell lineage lymphoproliferative disorders. Although flow cytometry is a useful tool, interpretation of the results can be challenging, because T-cells lack an easily analyzed structural element that can provide a surrogate marker of clonality such as immunoglobulin light chains on B-cells. Thus, routine T-cell phenotyping assays in the clinical laboratory require the comprehensive analysis of several T-cell-associated antigens. Although the detection of aberrant patterns of T-cell antigen expression can be helpful in establishing a diagnosis of T-cell malignancy, these patterns are not always disease specific, and some can overlap significantly with T-cell phenotypes observed in reactive conditions. Thus, arriving at an accurate diagnosis requires correlation of the flow cytometry results with the clinical, morphologic, and molecular results. Furthermore, the integration of these varied pieces of information into a cogent diagnosis requires an understanding of T-cell biology. In this review, the use of flow cytometry to identify T-cell lymphoproliferative disorders, particularly in peripheral blood and bone marrow specimens, is discussed, and a brief overview of T-cell biology to aid the reader in understanding the significance of the flow cytometry results is provided.
  Clinics in Laboratory Medicine 10/2007; 27(3):513-32, vi. · 1.97 Impact Factor
• Article: Images in pathology. Endometrial stromal sarcoma with hyalinizing giant rosettes and separate leiomyoma with palisading nuclei in the same uterus.

  Francois M Cady, Elisabetta Kuhn, John B Holt
  International Journal of Surgical Pathology 11/2006; 14(4):326-7. · 1.00 Impact Factor
• Article: Histologic patterns of polyethylene glycol-liposomal doxorubicin-related cutaneous eruptions.

  Francois M Cady, Rayna Kneuper-Hall, John S Metcalf
  [show abstract] [hide abstract]
  ABSTRACT: Polyethylene glycol (PEG)-liposomal doxorubicin (Stealth R, Doxil) is a formulation of doxorubicin, which is encapsulated in liposomes formulated with PEG. It is favored in the palliative setting over doxorubicin because of its generally favorable side effect profile. Adverse reactions are predominantly skin eruptions. We report 3 cases of women with breast cancer undergoing treatment with liposomal doxorubicin who developed palmar-plantar erythrodysesthesia and diffuse morbilliform eruptions. Biopsies in the 2 cases demonstrated vacuolar interface dermatitis with epidermal dysmaturation and the third case suggested a drug eruption. Additionally, we report a woman with metastatic breast cancer who developed a similar morbilliform eruption soon after completing a regimen of liposomal doxorubicin. The biopsy revealed an atypical squamous proliferation showing epidermal dysmaturation with focal evidence of interface damage. Both clinician and pathologist alike should be cognizant of this cutaneous eruption, as well as the histologic patterns.
  American Journal of Dermatopathology 05/2006; 28(2):168-72. · 1.20 Impact Factor
• Article: "Wreath cell" in recurrent anaplastic large cell lymphoma.

  J R McEvoy, Francois M Cady, Rana S Hoda
  Diagnostic Cytopathology 03/2006; 34(2):112-3. · 1.16 Impact Factor
• Article: Polypoid sinonasal lesion in a diabetic patient.

  Francois M Cady, James A Madory, Rana S Hoda
  Diagnostic Cytopathology 08/2004; 31(1):31-2. · 1.16 Impact Factor